Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Wednesday, 10 February 2021 09:15

Joshua Bauml

Written by
Joshua Bauml is an Assistant Professor fo Medicine at the Perelman School of Medicine at the University of Pennsylvania. His clinical and research interests focus on improving outcomes for patients with lung and head and neck cancers using translational research.
Wednesday, 10 February 2021 09:15

Mark Awad

Written by
Dr. Mark Awad is an Assistant Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. He received his undergraduate degree from Harvard University and his MD and PhD degrees from the Johns Hopkins School of Medicine. He completed his residency and chief residency at the Massachusetts General Hospital, and his medical oncology fellowship at the Dana-Farber Cancer Institute before joining the Dana-Farber faculty in 2014. His translational research focus is on identifying biomarkers of response and resistance to targeted therapies and immunotherapies in lung cancer. He is a recipient of the 2015 Young Investigator Award from the American Society of Clinical Oncology (ASCO), the 2015 Young Investigator Award from the International Association for the Society of Lung Cancer (IASLC), the 2017 Career Development Award from the Conquer Cancer Foundation of ASCO, and the 2018 ALK Positive/LUNGevity Transformational Research Award.
Wednesday, 10 February 2021 09:15

Kathryn Arbour

Written by
Kathryn C. Arbour is a thoracic medical oncologist with a clinical and translational research focus on developing immunotherapies and targeted therapies for patients with KRAS mutant non-small cell lung cancer. Dr. Arbour is currently an Assistant Professor at Memorial Sloan Kettering Cancer Center where she joined the faculty after completing her fellowship at Memorial. Her clinical research is focused on improvements in immunotherapy for lung cancer and specifically focused on patients with KRAS mutant lung cancer. Her clinical trial focus is concentrated on developing effective therapies for KRAS mutant NSCLC in patients with both G12C and non-G12C molecular subtypes. She serves as both a clinical investigator overseeing and developing clinical trials as well as a translational researcher identifying potential patterns of primary and acquired resistance to both immunotherapy and targeted therapies.
Wednesday, 10 February 2021 09:15

Valsamo Anagnastou

Written by
Dr. Anagnostou is a translational lung cancer investigator who is focusing on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients treated with immunotherapy. Dr. Anagnostou is an Assistant Professor of Oncology in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from National and Kapodistrian University of Athens, Greece and received a PhD in cancer biology from the same institution. Dr. Anagnostou completed her internal medicine residency at Yale-New Haven Hospital and subsequently trained in Medical Oncology at Johns Hopkins. Her main research focus is studying tumor evolution under the selective pressure of immune targeted agents and she has discovered novel mechanisms of acquired resistance to immune checkpoint blockade related to the evolving neoantigen landscape in resistant tumors. Dr. Anagnostou is developing liquid molecular assays that capture the dynamics of response and may more accurately predict emergence of resistance to immunotherapy. Her long term goal is to incorporate immunogenomic biomarkers in immuno-oncology clinical trial design as well as standard of care.
Wednesday, 10 February 2021 09:15

Dara Aisner

Written by
Dr. Dara Aisner is a board-certified certified Anatomic and Molecular Genetic Pathologist. She is an Associate Professor of Pathology at the University of Colorado School of Medicine in Denver, Colorado and a member of the University of Colorado Comprehensive Cancer Center. She is also board certified in Clinical Informatics. She is the Director of the Colorado Molecular Correlates Laboratory within the Department of Pathology. The laboratory provides CLIA level clinical services in the evaluation of patient tumor specimens for personalized medicine approaches. She is a member of numerous oncology pathology and guidelines committees including the CAP/AMP/IASLC Guidelines for Biomarker Testing in Non-Small Cell Lung Cancer, among others.
Wednesday, 10 February 2021 09:15

Charu Aggarwal

Written by
Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches including cellular therapy and CAR-T for solid tumors.
Wednesday, 10 February 2021 09:14

Alex Adjei

Written by
Alex A. Adjei is a Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo College of Medicine, in Rochester, MN. He oversees oncology drug development as well as lung cancer research and treatment across all 3 Mayo Clinic sites, and is co-Leader of the Developmental Therapeutics program at Mayo Cancer Center. Dr. Adjei has served on a number of US National Cancer Institute (NCI) committees. From 2007 to 2013, he was Chair of the NIH Study Section NCRR Clinical Research Review Committee, reviewing CTSAs. From 2010 – 2014, he was a Member of the Clinical Oncology Study Section (CONC), and from 2013-2017, he was a member of NCI IRG Subcommittee A, reviewing Cancer Centers. He is currently co-chair of the Thoracic Malignancies Steering Committee of NCI. He has served on various committees of professional societies. He was the President of the Minorities in Cancer Research Council of AACR and a member of the Board of Directors of IASLC and is currently Faculty Coordinator for Developmental Therapeutics and member of the Gender Medicine Task Force of ESMO.  Dr Adjei is serving on the Committee on Diagnosing and Treating Adult Cancers of the US National Academies of Sciences, Engineering and Medicine, tasked with providing a report on this topic to the US government (Social Security Administration). He is the Editor-in-Chief of the Journal of Thoracic Oncology and JTO Clinical and Research Report.

Dr. Adjei’s research is focused on experimental therapeutics and clinical drug development. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He also received the inaugural IASLC Adi  F. Gazdar Merit Award for Distinguished Service in Lung Cancer, in 2020. He has authored 290 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapies for lung cancer.
Tuesday, 04 August 2020 09:35

Chandra Belani

Written by

Dr. Chandra Belani is the Chief Science Officer of the IASLC. He directs the IASLC's scientific strategy, including research projects, publications, educational content for conferences. Dr. Belani also serves as a spokesperson for the IASLC at conferences, with the media and in meetings with partners and the community. Dr. Belani is also currently a Professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the Penn State Hershey Medical Center and College of Medicine in Hershey, PA. He is a lung cancer expert and a recognized thought leader.

Tuesday, 04 August 2020 09:35

Murry Wynes

Written by
Dr. Wynes is a senior advisor for scientific affairs at the IASLC and leads a number of global initiatives for the organization. Before joining IASLC in 2014 Dr. Wynes was an assistant professor at the University of Colorado in the Division of Medical Oncology, Department of Medicine, where he managed a laboratory researching and evaluating predictive and prognostic biomarkers, both protein- and nucleic acid-based, for small and non-small cell lung cancer. Prior to the University of Colorado Dr. Wynes was an instructor at National Jewish Health in Denver, Colorado where he conducted research in the field of idiopathic pulmonary fibrosis. Dr. Wynes has co-authored 50 peer-reviewed journal articles and a few book chapters. He served in the US Army as a surgical technician before earning a Bachelor’s of Science in Molecular and Microbiology from the University of Wyoming and then a Doctorate of Philosophy from the University of Colorado in immunology and microbiology.
Tuesday, 04 August 2020 09:20

Tetsuya Mitsudomi

Written by

IASLC President, Dr. Tetsuya Mitsudomiis a Professor of Thoracic Surgery at Kindai University Faculty of Medicine, Osaka-Sayama, Japan.  

Recipient of many prestigious awards, his current research interests include precision treatment of lung cancer based on cancer genotypes such as EGFR mutations or ALK translocations. He has published more than 400 papers in international peer-reviewed journals. 

Page 370 of 371